Results 71 to 80 of about 1,815 (184)

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Journal of Diabetes Investigation, 2019
Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor that is currently used to treat patients with type 2 diabetes mellitus.
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku   +7 more
doaj   +1 more source

Long‐term remission in gout: Challenges and future opportunities

Rheumatology &Autoimmunity, EarlyView.
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An important determinant of treatment decisions and long‐term follow‐up is the quality of the clinician–patient relationship. The “treat‐to‐target” approach
Patapong Towiwat, Zhanguo Li
wiley   +1 more source

NetMetaEasy: enabling rapid and user‐friendly network meta‐analysis (NMA) for comparative effectiveness research

British Journal of Pharmacology, EarlyView.
Background and Purpose Network meta‐analysis (NMA) enables the simultaneous comparison of multiple treatments by combining direct and indirect evidence across a network of studies. While its application is rapidly expanding in pharmacological research and clinical guideline development, performing NMA typically requires advanced statistical knowledge ...
János Tibor Fekete, András Komócsi, Balázs Győrffy   +2 more
wiley   +1 more source

Effects of short‐term tofogliflozin treatment on the insulin secretory capacity of people with type 2 diabetes: A randomized controlled trial, the TOP‐ELM study

Journal of Diabetes Investigation, EarlyView.
Tofogliflozin was compared with metformin in treatment‐naïve people with type 2 diabetes for 4 weeks. Overall insulin secretory capacity did not improve; however, tofogliflozin was associated with an improved disposition index in individuals with poorer baseline glucose tolerance or greater improvement after treatment.
Maiko Miyamoto, Aika Miya, Akinobu Nakamura, Yuka Takahashi, Yuki Yamauchi, Shingo Yanagiya, Takahiro Takase, Mayuko Ono, Kiyohiko Takahashi, Kazufumi Okada, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, on behalf of TOP‐ELM study group, Maiko Miyamoto, Aika Miya, Akinobu Nakamura, Hiraku Kameda, Kyu Yong Cho, Tatsuya Atsumi, Kazufumi Okada, Rimi Izumihara, Yuki Oe, Takahiro Takase, So Nagai, Akihiro Takahashi, Yuka Takahashi, Yuki Yamauchi, Hiromichi Kijima, Shinji Taneda, Jun Takeuchi, Kei Yokozeki, Saki Kuwabara, Yoshiaki Arimura, Shinichiro Kawata, Tomonori Sekizaki, Yuki Yamauchi, Shingo Yanagiya, Mayuko Ono, Kiyohiko Takahashi   +39 more
wiley   +1 more source

Ketoacidosis without significantly hyperglycaemia - is it possible?

Journal of Education, Health and Sport, 2017
Introduction and aim of the study. Currently only minimal information is available regarding ketoacidosis without significant hyperglycemia. Some study describe that the sodium –glucose cotransporters (SGLT) may alter the normal balance between ...
Michał Budzyński, Joanna Pekar, Justyna Magdalena Skolarczyk, Monika Tadla, Katarzyna Skórzyńska-Dziduszko   +4 more
doaj   +3 more sources

Influence of long term administration of tofogliflozin on chronic inflammation of visceral adipose tissue in mice with obesity induced by a high-fat diet.

PLoS ONE, 2019
We previously found that senescence of cluster of differentiation 4 (CD4) T cells is accelerated in the visceral adipose tissue (VAT) of mice with diet-induced obesity (DIO) due to a high-fat diet (HFD), and that these senescent-associated T cells cause ...
Kohsuke Shirakawa, Wataru Yano, Keisuke Inoue, Yoshinori Katsumata, Jin Endo, Motoaki Sano   +5 more
doaj   +1 more source

Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis

Cells, 2022
Ballooning degeneration of hepatocytes is a major distinguishing histological feature of non-alcoholic steatosis (NASH) progression that can lead to cirrhosis and hepatocellular carcinoma (HCC).
Kentaro Murakami, Yusuke Sasaki, Masato Asahiyama, Wataru Yano, Toshiaki Takizawa, Wakana Kamiya, Yoshihiro Matsumura, Motonobu Anai, Tsuyoshi Osawa, Jean-Charles Fruchart, Jamila Fruchart-Najib, Hiroyuki Aburatani, Juro Sakai, Tatsuhiko Kodama, Toshiya Tanaka   +14 more
doaj   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Advanced maternal age elevates the prevalence of hypertensive disorders in women of Japanese, independent of blood pressure: a study from the Japan Environment and Children’s study [PDF]

Hypertensive disorders of pregnancy (HDP) are leading causes of maternal and infant mortality, and maternal age is a known factor influencing maternal and pediatric outcomes during childbirth.
00633116, 00807646, 10210337, 20596879, 23302, 24118, 24294, 24631, 24690, 24695, 24779, 24901, 25026, 25039, 25511, 25512, 40803987, 60451936, 60550712, Akiyama, Yuka, Horiuchi, Sayaka, Kojima, Reiji, Kushima, Megumi, Miyake, Kunio, Ohoka, Tadao, Otawa, Sanae, Shinohara, Ryoji, the Japan Environment and Children’s Study Group, Tsuchiya, Kyoichiro, Uchinuma, Hiroyuki, Yamagata, Zentaro, Yokomichi, Hiroshi, アキヤマ, ユウカ, ウチヌマ, ヒロユキ, オオオカ, タダオ, オタワ, サナエ, クシマ, メグミ, コジマ, レイジ, シノハラ, リョウジ, ツチヤ, キョウイチロウ, ホリウチ, サヤカ, ミヤケ, クニオ, ヤマガタ, ゼンタロウ, ヨコミチ, ヒロシ, 三宅, 邦夫, 久島, 萌, 内沼, 裕幸, 土屋, 恭一郎, 堀内, 清華, 大岡, 忠生, 小島, 令嗣, 小田和, 早苗, 山縣, 然太朗, 横道, 洋司, 秋山, 有佳, 篠原, 亮次   +55 more
core   +1 more source